Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0917798 (
cerebral ischemia
)
17,036
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Carbenoxolone
(
CBX
) has a neuroprotective effect in experimental models of brain ischemia and trauma. However, systemic effect of
CBX
on ischemic reperfusion injuries has not been investigated in a temporary model of focal
cerebral ischemia
. Male Wistar rats (n = 32) were divided into control and
CBX
-treated (100, 200, or 400 mg/kg, intraperitoneally) groups. Transient focal
cerebral ischemia
was induced by 60-minute middle cerebral artery occlusion by filament method, followed by 23-hour reperfusion. At the end of 24-hour ischemia, neurologic deficit score was tested and infarct volumes were determined using triphenyltetrazolium chloride staining. Administration of
CBX
(100, 200, or 400 mg/kg) at the beginning of ischemia significantly reduced cortical infarct volumes by 48%, 58%, and 63%, and striatal infarct volumes by 34%, 63%, and 63%, respectively. Nevertheless,
CBX
has no effect on neurologic dysfunction. Our findings indicated that peripheral administration of
CBX
has a neuroprotective effect on postischemic damage in a temporary model of focal
cerebral ischemia
in rat.
...
PMID:Peripheral administration of carbenoxolone reduces ischemic reperfusion injury in transient model of cerebral ischemia. 1925 Nov 82
